See Supplemental Patient Information
- Vaccine should not be administered to children <24 months of age due to an increased risk of post-vaccination wheezing and hospitalizations
- Do not administer to individuals with asthma or children <5 yrs with recurrent wheezing due to the potential for increased risk of wheezing after vaccination unless the potential benefit outweighs the potential risk
- Individuals who have experienced Guillain-Barré syndrome within 6 wks after a previous influenza vaccination should not receive this vaccine unless the potential benefit outweighs the potential risk
- It is important to carefully weigh potential benefits and risks associated with the vaccine when administering to immunocompromised individuals
- Anaphylactic reactions may occur during vaccine administration; appropriate medical treatment and supervision should be readily available to manage possible anaphylactic reactions following vaccination
- Vaccine should not be administered until 48 hrs after the discontinuation of antiviral therapy; do not administer antiviral agents until 2 weeks after vaccine administration unless medically indicated
- Vaccination may not protect all persons
Cautions: Use cautiously in
- Immunocompromised persons
- Chronic disease predisposing to influenza complications
Supplemental Patient Information
- Inform the vaccine recipient or the parent/guardian that the vaccine is an attenuated live virus vaccine and has the potential for transmission to immunocompromised household contacts
Pregnancy Category:C
Breastfeeding: As per the Centers for Disease Control and Prevention and several health professional organizations, the vaccines administered to a nursing mother do not affect the safety of breastfeeding for mothers or infants. Maternal vaccination with live, attenuated (inhaled) influenza vaccine is not a contraindication to breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 June 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- FluMist LIQD [Syringe] (MEDIMMUNE)
1 = $30.99
3 = $71.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
